Francis P. Worden, MD, discusses how the effectiveness of lenvatinib in this real-world setting compares with results from ...
Sonodynamic therapy doubled the median overall survival to 15.7 months and tripled progression-free survival to 5.5 months in ...
The approval of durvalumab, based on data from the phase 3 ADRIATIC study, offers a new standard of care for patients with ...
Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the CEPHEUS trial results and impact on frontline treatment in ...
During a Case-Based Roundtable meeting, Lipson and participants talked about the complexity of choosing the right therapy for ...
The FDA granted breakthrough therapy status to sacituzumab tirumotecan in EGFR-mutated advanced non–small cell lung cancer.
Enrollment in cohort 5 of the phase 1/2 GOBLET study will resume after the Data Safety Monitoring Board’s safety review.